Ensign Peak Advisors Inc Has $31.56 Million Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Ensign Peak Advisors Inc lowered its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 2.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 570,056 shares of the company's stock after selling 16,974 shares during the quarter. Ensign Peak Advisors Inc owned about 1.49% of Tarsus Pharmaceuticals worth $31,564,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Crowley Wealth Management Inc. bought a new stake in Tarsus Pharmaceuticals in the fourth quarter worth about $25,000. R Squared Ltd bought a new stake in Tarsus Pharmaceuticals in the fourth quarter worth about $53,000. Quarry LP bought a new stake in Tarsus Pharmaceuticals in the fourth quarter worth about $166,000. HighTower Advisors LLC bought a new stake in Tarsus Pharmaceuticals in the fourth quarter worth about $207,000. Finally, Summit Investment Advisors Inc. raised its position in Tarsus Pharmaceuticals by 6.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock worth $213,000 after acquiring an additional 244 shares in the last quarter. Institutional investors and hedge funds own 90.01% of the company's stock.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, CEO Bobak R. Azamian sold 7,131 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total transaction of $330,093.99. Following the completion of the sale, the chief executive officer now directly owns 70,720 shares of the company's stock, valued at $3,273,628.80. This trade represents a 9.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Dianne C. Whitfield sold 2,315 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $107,161.35. Following the completion of the transaction, the insider now owns 50,751 shares in the company, valued at $2,349,263.79. This represents a 4.36% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,542 shares of company stock worth $1,581,173. 8.25% of the stock is currently owned by company insiders.

Analyst Ratings Changes

TARS has been the topic of several research reports. Barclays dropped their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Jefferies Financial Group boosted their price target on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th. Oppenheimer upped their price objective on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. Guggenheim lifted their target price on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Finally, The Goldman Sachs Group boosted their price target on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a report on Monday, May 5th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $66.33.

Tarsus Pharmaceuticals Trading Down 6.2%

Shares of NASDAQ:TARS traded down $2.74 during mid-day trading on Tuesday, hitting $41.46. The stock had a trading volume of 1,557,432 shares, compared to its average volume of 694,392. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The company has a market cap of $1.74 billion, a PE ratio of -10.88 and a beta of 0.94. Tarsus Pharmaceuticals, Inc. has a 12-month low of $20.08 and a 12-month high of $57.28. The company's 50 day moving average is $48.21 and its 200-day moving average is $49.19.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. The company had revenue of $78.34 million for the quarter, compared to the consensus estimate of $72.50 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. On average, sell-side analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.